Press Releases

 Filter by Provider

ABBYY today announced the issuance of 22 new patents in the past two years, reinforcing its position as a global leader in purpose-built AI for document process automation. Spanning innovations in language detection, user interface design, image identification, information extraction, and document decoding, these patents expand ABBYY’s total patent portfolio to more than 400 patents and patent applications worldwide.

Abcuro, Inc., today announced topline results from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients with inclusion body myositis (IBM), a rare, debilitating and relentlessly progressive chronic autoimmune disease that currently has no approved treatment options. The MUSCLE study did not meet its primary endpoint, assessed by the IBM Functional Rating Scale (IBMFRS) total score at Week 76 compared to placebo, or key secondary endpoints. While the results did not achieve statistical significance, a pre-specified subgroup analysis in patients with mild to moderate disease at baseline showed trends in improvement in the IBMFRS total score and key secondary endpoints, suggesting the potential of ulviprubart’s disease modifying activity in such patients. Importantly, ulviprubart showed a favorable safety and tolerability profile compared to placebo, and no safety signals were identified at the doses studied.

Generation Mining Limited (TSX: GENM) (“Gen Mining” or the “Company”) is pleased to announce the appointment of Rachel Pineault, Executive Vice President Corporate Affairs and Human Resources and Erich Meintjes, Vice President Engineering to the Generation Mining Management Team to support the development, construction, and future operation of the Company’s Marathon Copper-Palladium Project in Northwestern Ontario.

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.

PCA Global Ventures, a global leader in compassionate customer care and specialized debt recovery collection solutions, today announced a new partnership with Wilmington University to deliver a comprehensive, company-wide artificial intelligence training program. The initiative represents PCA Global Ventures’ first education collaboration with a local university and underscores the company’s continued investment in workforce development, innovation, and community engagement.

Bowhead Specialty Holdings Inc. (NYSE: BOW), a specialty lines insurance group focused on providing casualty, professional liability and healthcare liability insurance products, delivered through complementary “craft” and “digital” underwriting models, today announced financial results for the fourth quarter and year ended December 31, 2025(1).

Albany International Corp. (NYSE:AIN) today reported operating results for its full year and for its fourth quarter of 2025, which ended December 31, 2025.

Fingerprint, a leader in device intelligence for fraud prevention, today announced strong momentum for fiscal year 2026. As enterprises increasingly turn to Fingerprint’s platform to detect AI-driven fraud, the company achieved 65% growth in annual recurring revenue (ARR), with adoption spanning financial services, fintech, SaaS, e-commerce and travel and hospitality. Fingerprint's device intelligence platform now identifies over 1 billion unique devices per month, a 77% year-over-year increase.

TelevisaUnivision, the world's leading Spanish-language media company, today announced financial results for the fourth quarter and full year ended December 31, 2025. Please visit the company’s Investor Relations website at investors.televisaunivision.com to view the financial results and earnings materials.

Moody’s Corporation (NYSE: MCO) announced today that Michael West, President of Moody’s Investors Service, will speak at the Raymond James Annual Institutional Investors Conference on Tuesday, March 3, 2026. The presentation will begin at approximately 10:25 a.m. Eastern Time and will be webcast live.

Yukon Partners (“Yukon”), a provider of junior capital for middle market private equity transactions, is pleased to announce it has partnered with The Riverside Company (“Riverside”) to support its investment in Western Botanicals (the “Company”).

The City of St. Petersburg completed a major resilience upgrade at its Northeast Water Reclamation Facility with the installation of the patented FRA Flood Panel system from Flood Risk America, strengthening the facility’s ability to remain operational during hurricanes and storm surge events.

– Record Quarterly Revenue of $148.3 million –

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmology and Therapy published a new global narrative review examining the causes, burden and management of noninfectious conjunctival hyperemia (ocular redness). The review highlights the growing global prevalence of ocular redness driven by digital lifestyles, dry eye, contact lens wear, allergies and environmental factors, reinforcing how ocular redness affects both comfort and appearance.1

908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will participate in the following investor conferences.

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 –

PLYMOUTH, Mich. and ROLLE, Switzerland, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Garrett Motion Inc. (Nasdaq: GTX) ("Garrett" or the "Company"), a leading differentiated automotive technology provider today announced its participation in the upcoming investor conference:

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Nations Royalty Corp. (TSX-V: NRC; OTCQX: NRYCF), a royalty company focused on creating royalty diversification for First Nations and Indigenous groups, has qualified to trade on the OTCQX® Best Market. Nations Royalty Corp. upgraded to OTCQX from the OTCQB® Venture Market.

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the TD Cowen 46th Annual Health Care Conference and The Citizens Life Sciences Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus 

Aspect announces Aspect Intelligence™, its newest capabilities designed to help enterprises move from static workforce planning to ongoing, real-time operational control.

MONTVALE, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference.

VANCOUVER, Canada, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO, OTCQB: ORRCF) (the “Company” or “Oroco”) is pleased to announce that it has mobilized a diamond drill rig to its Santo Tomás copper project, located in northwestern Mexico, to commence drilling intended to support the upgrade of the mineral resource classifications in the project’s South Zone.

ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025.

CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2025 and its initial 2026 outlook.

Rebrands to Cipher Digital to Reflect Strategic Shift Toward HPC

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced its participation in the following upcoming investor conferences:

― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ―

LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences.

RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences:

Aptose Biosciences and Hanmi Pharmaceutical to Further Extend Loan Agreement to Continue Development of Tuspetinib in Frontline Triplet Therapy for AML

Palo Alto, California, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or the “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced that it will attend Enforce Tac 2026, Germany’s prominent trade fair for security and defense, being held February 23–25, 2026, in Nuremberg, Germany.

News Highlights

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

~30% Quarterly Revenue Growth Driven by Amtagvi Demand

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced GR Silver Mining Ltd. (TSX-V: GRSL; OTCQX: GRSLF), a Canadian-based, Mexico-focused mineral exploration company, has qualified to trade on the OTCQX® Best Market. GR Silver Mining Ltd. upgraded to OTCQX from the OTCQB® Venture Market.

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46th Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors.

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term

50% Objective Response Rate (ORR) in Advanced Sarcomas

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the CLARITY Phase 3 trial of solriamfetol in the treatment of major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms.

WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026.

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Dryden Gold Corp. (TSX-V: DRY; FSE: X7W; OTCQX: DRYGF), a junior gold exploration company, has qualified to trade on the OTCQX® Best Market. Dryden Gold Corp. upgraded to OTCQX from the OTCQB® Venture Market.

BANNOCKBURN, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2025.

First physical delivery validates the Company's integrated gold market infrastructure in Singapore

PORTLAND, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals”) (NASDAQ: SHLS), a global leader in electrical infrastructure solutions for the energy transition market, and ON.energy, a developer of custom grid-safe power architecture, today announced an agreement to deploy multiple gigawatts of critical power systems into the AI data center market.

PRINCETON, N.J. and SUZHOU, China, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics today announced that members of its senior leadership team will participate in the 36th Annual Oppenheimer Healthcare Life Sciences Conference February 25-26, 2026.

MONTRÉAL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OR Royalties Inc. (“OR Royalties” or the “Company”) (OR: TSX & NYSE) is pleased to announce that it has entered into a definitive agreement to acquire Terraco Gold Corp. (“Terraco”), a wholly-owned subsidiary of Sailfish Royalty Corp., which indirectly owns net smelter return (“NSR”) royalty assets (the “NSR Royalties”), largely consisting of royalties that cover Solidus Resources LLC’s (“Solidus”) Spring Valley Gold Project (“Spring Valley” or the “Project”) located in Pershing County, Nevada, USA. OR Royalties is acquiring Terraco and the NSR Royalties for total cash consideration of $168 million (the “Transaction”). The Transaction is subject to the approval of the TSX Venture Exchange and other customary closing conditions, and is expected to be completed in the first half of 2026. Amounts presented are in United States dollars, except where otherwise noted.

PRESS RELEASE